Last reviewed · How we verify
transferrin-CRM107
At a glance
| Generic name | transferrin-CRM107 |
|---|---|
| Sponsor | Xenova Biomedix |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma (PHASE1)
- Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors (PHASE3)
- Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- transferrin-CRM107 CI brief — competitive landscape report
- transferrin-CRM107 updates RSS · CI watch RSS
- Xenova Biomedix portfolio CI